Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies

Breast care

J. Barth¹  Christian Jackisch¹  Michael Untch¹ 

[1] aStiL (Study Group of Indolent Lymphomas) Central Office, Med Klin IV, Justus-Liebig-University Giessen, Offenbach, Germany

关键词: Molecular mechanisms of pharmacological action;    Antibodies;    Receptor protein tyrosine kinases;   

DOI  :  10.1159/000190063

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

In recent years, new classes of molecules have been established as opportunities for the treatment of breast cancer. The approval of trastuzumab, the antibody against Her2/neu, in the late 1990s was followed by the approval of the antiangiogenic antibody bevacizumab in 2007. Progress in the understanding of the molecular mechanisms of carcinogenesis and tumour growth led to the development of new molecules, mostly kinase inhibitors. A few of these new molecues gained approval in several countries; clinical trials aiming at further approvals are ongoing. This short review covers the actual state-of-the-art and possible future developments in the targeted therapy of breast cancer.

【 授权许可】

Unknown